{"id":"syn023","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Rash"},{"rate":"1-5%","effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, SYN023 prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.","oneSentence":"SYN023 is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:05.257Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT03961555","phase":"PHASE2","title":"Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2019-09-03","conditions":"Rabies","enrollment":448},{"nctId":"NCT07342257","phase":"PHASE1","title":"SYN023 With Rabies Vaccine in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2024-11-30","conditions":"Rabies Post-exposure Prophylaxis","enrollment":108},{"nctId":"NCT07327307","phase":"","title":"Real World Evidence Study of SYN023 in Children Exposed to Rabies","status":"RECRUITING","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2025-08-02","conditions":"Rabies Post-exposure Prophylaxis","enrollment":232},{"nctId":"NCT04644484","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2020-09-23","conditions":"Rabies, Communicable Disease, Virus Diseases","enrollment":1000},{"nctId":"NCT04495569","phase":"PHASE1, PHASE2","title":"A Bridging Study of the SYN023 on Healthy Adult Subjects","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2019-02-26","conditions":"Communicable Disease Transmission, Zoonotic Disease, Rabies Human","enrollment":33},{"nctId":"NCT02956746","phase":"PHASE1, PHASE2","title":"A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2016-08","conditions":"Human Rabies","enrollment":164}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zamerovimab and Mazorelvimab Injection","A Humanized Anti-Rabies Molecular antibodies cocktails"],"phase":"phase_3","status":"active","brandName":"SYN023","genericName":"SYN023","companyName":"Synermore Biologics Co., Ltd.","companyId":"synermore-biologics-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"SYN023 is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}